10-May-2024
No headlines found.
Agios to Present at the BofA Securities 2024 Health Care Conference on May 16, 2024
Globe Newswire (Mon, 6-May 7:00 AM ET)
Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 14, 2024
Globe Newswire (Fri, 3-May 7:00 AM ET)
Agios Reports Business Highlights and First Quarter 2024 Financial Results
Globe Newswire (Thu, 2-May 7:00 AM ET)
Agios to Webcast Conference Call of First Quarter 2024 Financial Results on May 2, 2024
Globe Newswire (Thu, 18-Apr 7:00 AM ET)
Agios Publishes 2024 Environmental, Social and Governance (ESG) Report
Globe Newswire (Tue, 9-Apr 7:00 AM ET)
Agios to Present at the Leerink Partners Global Biopharma Conference on March 12, 2024
Globe Newswire (Tue, 5-Mar 7:00 AM ET)
Agios to Present at the TD Cowen 44th Annual Health Care Conference on March 4, 2024
Globe Newswire (Thu, 22-Feb 7:00 AM ET)
Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
Globe Newswire (Thu, 15-Feb 7:00 AM ET)
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
Agios Pharmaceuticals trades on the NASDAQ stock market under the symbol AGIO.
As of May 10, 2024, AGIO stock price climbed to $33.00 with 489,071 million shares trading.
AGIO has a beta of 1.37, meaning it tends to be more sensitive to market movements. AGIO has a correlation of 0.16 to the broad based SPY ETF.
AGIO has a market cap of $1.87 billion. This is considered a Small Cap stock.
Last quarter Agios Pharmaceuticals reported $8 million in Revenue and -$1.45 earnings per share. This fell short of revenue expectation by $-181,000 and exceeded earnings estimates by $.20.
In the last 3 years, AGIO stock traded as high as $62.16 and as low as $16.75.
The top ETF exchange traded funds that AGIO belongs to (by Net Assets): XBI, VTI, IWM, VB, VXF.
AGIO has outperformed the market in the last year with a price return of +27.9% while the SPY ETF gained +27.8%. AGIO has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +31.3% and +4.8%, respectively, while the SPY returned +4.2% and +2.5%, respectively.
AGIO support price is $31.97 and resistance is $33.87 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AGIO stock will trade within this expected range on the day.